ProCE Banner Activity

Optimizing Management of Patients With Cardiometabolic and Renal Disease: A Case-Based Multidisciplinary Discussion


Download these slides for expert reviews on the role of SGLT2 inhibitors in cardiometabolic and renal disease.

Released: December 09, 2022

Expiration: December 08, 2023

No longer available for credit.



Jennifer B. Green

Jennifer B. Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Viet Le

Viet Le, DMSc, PA-C, FACC, FAHA, HF-Cert

Associate Professor of Research, Preventive Cardiology PA
Intermountain Heart and Vascular Clinical Program
Intermountain Health, Canyons Region
Salt Lake City, Utah

Matthew Weir

Matthew Weir, MD

Professor and Director
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Provided by

ProCE Banner


Academy of Physician Associates in Cardiology

ProCE Banner

Faculty Disclosure

Jennifer B. Green MD: consultant/advisor/speaker: Anji, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Novo Nordisk, Pfizer, Sanofi/Lexicon, Valo, Vertex; researcher: Boehringer Ingelheim/Lilly, Merck, Roche.

Viet Le, MPAS, PA-C: researcher (paid to institution): Amarin, Lilly, Milestone, Novartis

Matthew Weir, MD: advisor: Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novo Nordisk, Vifor.

Additional Information

Program Medium

This program has been made available online.